Quarterly report pursuant to Section 13 or 15(d)

Consolidated Interim Consolidated Balance Sheets

v3.19.1
Consolidated Interim Consolidated Balance Sheets - USD ($)
Feb. 28, 2019
Nov. 30, 2018
CURRENT    
Cash and cash equivalent $ 350,929 $ 1,182,387
Accounts receivable 17,868 18,914
Inventory 315,640 129,121
Prepaid expenses and other receivables 678,494 901,247
Total Current Assets 1,362,931 2,231,669
Patent rights 104,501 106,334
Deposit for equipment 225,124 205,664
Property and equipment 201,704 113,418
TOTAL ASSETS 1,894,260 2,657,085
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 460,946 397,309
Deferred revenue 52,525  
Secured convertible debentures 1,019,374 978,361
Derivative liabilities 563,602 957,301
Total Current Liabilities 2,096,447 2,332,971
Long term convertible notes 239,149 167,077
Total Liabilities 2,335,596 2,500,048
Capital stock    
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Nil issued and outstanding (November 30, 2018 - nil).
Common stock, $0.001 par value 200,000,000 shares authorized, 103,093,442 issued and outstanding (November 30, 2018: 101,976,900) 103,094 101,977
Additional paid-in capital 33,629,717 33,341,695
Accumulated deficit (34,136,110) (33,252,338)
Accumulated other comprehensive loss (38,037) (34,297)
Total Stockholders' (Deficiency) Equity (441,336) 157,037
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY $ 1,894,260 $ 2,657,085